Past Events

January 31- JP Morgan Healthcare Conference Recap


November 15, 2022: Scaling at the Speed of Change

Frances Johnson, COO, Viewpoint Molecular Targeting

John McCabe, CFO, Orna Therapeutics

Molly Robb, Managing Partner, Diversified Search

Rob MacDougall, CEO, MarathonLS

Moderated by Joe Goldberg, National Life Sciences Industry Consulting Leader, RSM US

October 18, 2022: Data Ownership

Guarav Singal, Physician, Brigham & Women's Hospital

Glenn Cohen, Deputy Dean, Harvard Law School

Jared Kesselheim, Managing Partner, Transformational Capital

Moderated by Julia Hesse, Partner, Healthcare Group, Choate Hall & Stewart LLP

September 12, 2022: Virtual Clinical Trials: Are they here to Stay?

Amanda McEwen, VP, Clinical Development, Elevian Therapeutics

Jennifer Cormier, SVP, Clinical Operations, PepGen

Laurie Halloran, President & CEO, Halloran Consulting Group, Inc

Moderated by Sean Wall, PPD, part of Thermo Fisher Scientific

June 6, 2022: Opportunities & Challenges with Cell & Gene Therapies

Tina Liu, Co-Founder, Skylark Bio

Lantz Mackey, Cell Therapy Development, Novartis

Tino Quintero, Chief Commercial Officer, Locus Biosciences

Chandra Ramanathan, EIR, MassGeneral Brigham

Moderated by Elizabeth Woo, VP & General Manager, Cell & Gene Therapies,

Thermo Fisher Scientific

April 28, 2022: The Challenges of Being a Public Company

Gregg Beloff, Managing Director, Danforth Advisors

Aoife Brennan, CEO, Synlogic, Inc

Scott Hansen, Head, Life Sciences, Venture Banking, Pacific Western Bank

Ivana Liebisch, CEO & President, Vigil Neuroscience

Moderated by Bruce Booth, Partner, Atlas Venture

March 15, 2022: Therapeutic Interventions for Healthy Aging

Tom Hughes, CEO, Navitor Pharmaceuticals

Joan Mannick, Co-founder and CEO, Tornado Therapeutics

Moderated by Jens Eckstein, Partner, Apollo Health Ventures

February 3, 2022: Cultivating the Next Generation

Abe Ceesay, President, Cerevel Therapeutics

Paula Soteropoulos, Chairman of the Board, Ensoma

Alan Walts, Venture Partner, Advent Life Sciences

Moderated by Dave Melville, Founder & CEO, The Bowdoin Group

December 1, 2021: Holiday Cocktail & Wine Tasting Reception

November 16, 2021: The Pros & Cons of Controversial FDA Approvals

Art Krieg, CSO & Founder, Checkmate Pharmaceuticals

Christine McSherry, CEO, Casimir LLC

Erin Mistry, SVP Payer Strategy, Government Affairs & Trade, Cormedix

Martin Tolar, CEO, Alzheon

Moderated by Katie Brandt, Director, Caregiver Support Services & Public Relations, Mass General

Hospital Frontotemporal Disorders Unit

November 2, 2021: Cybersecurity Awareness: Protecting Yourself & Your Company

Ileana van der Linde, Executive Director, JP Morgan Cybersecurity Awareness

Global Program

October 18, 2021: The Rising Asymmetry in Deal Terms across our Ecosystem

John Delyani, CBO, Repertoire Immune Medicines

Lauren Foster, Director, MIT Life Sciences Technology Licensing Team

Michal Preminger, Head, Johnson & Johnson Innovation

Moderated by Brian Goldstein, Partner, Choate Hall & Stewart

September 13, 2021: Long-Term Planning in a Bull Market

Mike Gilman, CEO, Arrakis Therapeutics

Scott Hansen, EVP & Head of Life Sciences Venture Banking, Pacific Western Bank

Holly Whittemore, CFO, Nimbus Therapeutics

Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities

June 15, 2021: The SPAC Attack

Gregg Beloff, Managing Director, Danforth Advisors

Jason Meyenburg, CEO, Gemini Therapeutics

Geoff Meyerson, CEO & Co-founder, Locust Walk

May 11, 2021: The Future of RNA Therapies

Frank DeRosa, CTO, Translate Bio

Robert Meehan, Sr. Director, Clinical Development, Moderna

Jennifer Petter, Founder & CSO, Arrakis Therapeutics

Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities

April 7, 2021: Tax Policy Changes

Adam Frank, Head of Wealth Management, JP Morgan Securities

Fred Gordon, Sr. Director, National Tax, RSM

Moderated by Chris Cavallo, Partner, Tax Services, RSM

March 15, 2021: The Future of the JPM Healthcare Conference

Angus Grant, Chief Business Executive, BeiGene

Lis Leiderman, CFO & Head of Corporate Development, Decibel Therapeutics

Moderated by David Ke, Managing Director, Investment Banking, JP Morgan Securities

February 23, 2021: Leadership during COVID

Chris Garabedian, CEO, Xontogeny

Jodie Morrison, CEO, Cadent Therapeutics

Ramani Varanasi, President & CEO, X-Biotix Therapeutics

Moderated by Jennifer Reilly, President & COO, Safety Partners

October 13, 2020: Fundraising during a Pandemic (part 2)

Doug Carlson, CFO, Ikena Oncology

Nilesh Kumar, Partner, Novo Ventures

Scott Hansen, EVP, Head of Life Sciences, Pacific Western Bank

Brian Gallagher, Partner, Abingworth

September 24, 2020: Fundraising during a Pandemic

Stuart Chaffee, CBO, Praxis Medicines

Brian Gallagher, Partner, Abingworth

Keith Dionne, CEO, Casma Therapeutics

John Gustofson, Managing Director, AbbVie Ventures

February 3, 2020: Top Considerations when Engaging a Potential Strategic Partnership

Mary Lynne Hedley, President & COO, Tesaro

Briane Fenton, CBO, Translate Bio

Maude Tessier, CBO, Ikena Oncology

Moderated by Imran Nasrullah, Director, Strategic Partnering, BD & L, Boehringer-Ingelheim

December 2019: Building your C-Suite

Stuart Chaffee, CBO, Praxis Medicines

Michelle Doig, Partner, Omega Funds

Chris Robinson, Chief Talent Officer, Third Rock Ventures

Moderated by Keiran English, Partner, Spencer Stuart

October 2019: The Evolving Role of Artificial Intelligence & Blockchain Technology in Drug Discovery

Rosana Kapellar, EIR, Google Ventures

Arthur Hiller, Chief Corporate Development Office, Nuritas

Bennett Moore, Lead Digital Asset Resource, RSM US

Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities

September 2019: The Nuts & Bolts of Company Formation

Paulina Hill, Partner, Omega Funds

Samantha Truex, CEO, Quench Bio

Brian Goldstein, Partner, Choate Hall & Stewart

Scott Hansen, Managing Director, Pacific Western Bank

Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities

May 2019: Charles River Fever: Is a Cambridge Address Necessary for Success?

Robert Urban, Former/Retired Global Head, Johnson & Johnson Innovation, LLC

Jim Broderick, CEO, Palleon Pharmaceuticals

Paula Cloghessy, Chief Human Resources Officer, Translate Bio

Dave Melville, CEO & Founder, The Bowdoin Group

Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities

March 2019: Measuring Readiness and Preparing your IPO

Reenie McCarthy, CEO, Stealth Biotherapeutics

John Maxwell, CFO, Aquestive Therapeutics

Gregg Beloff, Managing Director, Danforth Advisors

Moderated by Greg Schernecke, Partner at Dechert LLP

February 2019: Company Growth & Evolution of the Board

Praveen Tipirneni, CEO, Morphic Therapeutics

Bill Collins, Partner, Life Sciences Practice at Goodwin

Bruce Rycklik, Managing Partner at Park Square Executive Search

Moderated by Bruce Ledoux, JP Morgan Securities

December 2018: Policy, Pricing & Patient Affordability: A Discussion on Reimbursement

Amitabh Chandra, Harvard Business School and Harvard Kennedy School of Government

Jamey Millar, GlaxoSmithKline

Moderated by Bruce Ledoux, JP Morgan Securities

October 2018: Patent Strategy & Management: IP Diligence for Companies & Investors & Maximizing Portfolio ROI

John McDonald, Biogen

Paul Burgess, Translate Bio

Karen Sinclair, Harvard University

Moderated by Andrea Reid, Dechert LLP

September 2018: The Evolution of Finance

Steve Robinette, Atlas Ventures

David Ke, JP Morgan

Michal Preminger, J&J Innovation Center

Brian Goldstein, Choate, Hall & Stewart LLP

Moderated by Bruce Ledoux, JP Morgan Securities

May 2018: Structuring of Equity Compensation Models

Jeb Keiper, Nimbus Therapeutics

Paula Cloghessy, Translate Bio

Anne Longmire, JP Morgan Securities

Ram Kumar, Radford

Moderated by Bruce Ledoux, JP Morgan Securities

April 2018: Analysis of Oligonucleotides: Pros & Cons of Various Analytical Platforms

David Citerone, Frontage Laboratories

Jing Li, Alnylam Pharmaceuticals

February 2018: Tax Reform and its Implications to the Biotech Executive

Adam Frank, JP Morgan Securities

Robert McDonald, Partner, RSM

Moderated by Bruce Ledoux, JP Morgan Securities

November 2017: Strategic vs IPO: A Point & Counterpoint Discussion

Ron Renaud, CEO, Translate Bio

Doug Fambrough, CEO, Dicerna Pharmaceuticals

Moderated by Bruce Ledoux, JP Morgan Securities

October 2017: Advances in Biomolecule Analysis: A CMC Perspective

X. Sunney Xie- Harvard University

Desiree Tsao- Momenta Pharmaceuticals

Min Zhao- Frontage Labs

June 2017: Maximizing Value in a Merger & Acquisition or IPO Transaction

Phil Ross, JP Morgan

April 2017: Approaches to Immunogenicity Validations and the Impact of the Data on Early Clinical Development

Kevin Carleton- inVentiv Health

Susan Sloan- Visterra, Inc.

March 2017: Real World Evidence: The Convergence of Commercial & Clinical

David Thompson- inVentiv Health

Paul Hodgkins- Vertex

Arthur Hiller- Antyllus Therapeutics

Bryan Katz- inVentiv Health

December 2016: Holiday Cocktail Party

November 2016: Investigations into ISR (Incurred Sample Reproducibility) Failures

Pierre-Yves Caron- inVentiv Health

Case Studies presented by Krista Condon (Eisai), Eric David (Biogen), Estela Skende (Sunovion),

Heidi Mangus (Agios), and Mark Milton (Novartis)

September 2016: Regulatory Strategy

Carolyn Finkle- inVentiv Health

Stephane Lamouche- inVentiv Health

June 2016: Bioanalytical Challenges in Gene & Cellular Therapies and Biotherapeutics

Lilian Yengi- Bluebird Bio

Thomas Oglesby- inVentiv Health

May 2016: Commercial Viability

Angus Bromley- inVentiv Health

Waynne Waterfield- inVentiv Health

Arthur Hiller- Commercial Strategy Consultant

March 2016: Use of Proteomics to Identify Biomarkers

Richard Lipscombe- Proteomics International

Ru Wei- Biogen

Sept 2015: QT Assessments in Early Phase Trials

Borje Darpo- iCardiac Technologies, Inc

Sherilyn Adcock- Worldwide Clinical Trials

June 2015: CRO Selection: What are you looking for in your CRO Partner?

Liyu Yang- Biogen

Jim Vath- Zafgen

Peter Benton- Worldwide Clinical Trials

March 2015: Use of Adaptive Protocols in Drug Development

Jim Gilbert- True North Therapeutics

Gordon Loewen- Forum Pharmaceuticals

Darrell Nix- Drug Development Consulting

Sept 2014: When Novelty is not Enough: Creating Value Early and Throughout the Development Process

Mike Murphy- Worldwide Clinical Trials

May 2014: Use of Radiolabeled Studies in your Development Program

Wim Tamminga- QPS

Eric Solon- QPS

Jan 2014: The New Draft FDA BMV Guidance

September 2013: Validation of Biomarkers in the Bioanalytical Lab

Juan Chavez- Biogen

Jeff Moran- QPS

June 2013: Development of Bioanalytical Strategies for Characterization of Antibody Drug Conjugates (ADCs)

Dawn Dufield- Pfizer

Seema Kumar- Pfizer

March 2013: Issues with Metabolites

Caroline Lee- QPS

Jan 2013: Challenges in Alzheimer's Drug Development

Manfred Windisch- QPS (formerly JSW Life Sciences)

Oct 2012: Combining Autoradiography and Bioanalytical Techniques in Drug Discovery

Grace Poon- Syndexa

Eric Solon- QPS

June 2012: Preclinical Data Frontloading: An ADMET Perspective

Sanjeev Thohan, Novartis

Jian Yu- QPS

Jan 2012: New EMA BMV Guidance

Jeff Moran- QPS

Oct 2011: Protein analysis by LC-MS/MS

Joe Palandra- Pfizer

Ben van Baar- QPS

June 2011: Tissue Bioanalysis

Stacy Ho - Genzyme

Zamas Lam - QPS

March 2011: Dry Blood Spot

Krista Condon - Eisai

Jaap Weiling - QPS